HTG Molecular Diagnostics, Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2017. For the quarter, the company expects revenue to be between $6.9 million and $7.2 million. Gross margin and net loss in the fourth quarter are expected to be improved over the third quarter of 2017, primarily as a result of collaboration profit-sharing revenue expected to be recognized in the fourth quarter. For the year, the company expects total revenue for the full year 2017 is expected to be between $13.8 and $14.1 million, an increase of 169% to 175% over total revenue for the full year 2016. Collaboration revenue drove fourth quarter and full year 2017 revenue. The company is providing initial revenue guidance for the year ending December 31, 2018 in the range of $20.0 to $25.0 million.